Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
Want to see OTLC full AI Analyst Report?
Total Valuation
Oncotelic Therapeutics has a market cap or net worth of $16.70M. The enterprise value is $16.18T.
Market Cap$16.70M
Enterprise Value$16.18T
Share Statistics
Oncotelic Therapeutics has 444,197,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding444,197,020
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oncotelic Therapeutics’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is >-0.01%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)>-0.01%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee9.58T
Employee Count26
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oncotelic Therapeutics is <0.1. Oncotelic Therapeutics’s PEG ratio is -0.00002.
PE Ratio<0.1
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow-11.81
PEG Ratio-0.00002
Income Statement
In the last 12 months, Oncotelic Therapeutics had revenue of 0.00 and earned 249.28M in profits. Earnings per share was 0.59.
Revenue0.00
Gross Profit0.00
Operating Income-3.19M
Pretax Income360.57M
Net Income249.28M
EBITDA-3.19M
Earnings Per Share (EPS)0.59
Cash Flow
In the last 12 months, operating cash flow was -1.38M and capital expenditures -3.00, giving a free cash flow of -1.38M billion.
Operating Cash Flow-1.38M
Free Cash Flow-1.38M
Free Cash Flow per Share>-0.01
Dividends & Yields
Oncotelic Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.21
52-Week Price Change-33.93%
50-Day Moving Average0.04
200-Day Moving Average0.07
Relative Strength Index (RSI)49.97
Average Volume (3m)410.07K
Important Dates
Oncotelic Therapeutics upcoming earnings date is May 25, 2026, TBA (Confirmed).
Last Earnings DateApr 16, 2026
Next Earnings DateMay 25, 2026
Ex-Dividend Date―
Financial Position
Oncotelic Therapeutics as a current ratio of 0.07, with Debt / Equity ratio of 6.19%
Current Ratio0.07
Quick Ratio0.07
Debt to Market Cap492.95K
Net Debt to EBITDA-5.08M
Interest Coverage Ratio-3.60
Taxes
In the past 12 months, Oncotelic Therapeutics has paid 111.55M in taxes.
Income Tax111.55M
Effective Tax Rate0.31
Enterprise Valuation
Oncotelic Therapeutics EV to EBITDA ratio is -5.08M, with an EV/FCF ratio of -11.70.
EV to Sales0.00
EV to EBITDA-5.08M
EV to Free Cash Flow-11.70
EV to Operating Cash Flow-11.70
Balance Sheet
Oncotelic Therapeutics has $88.86B in cash and marketable securities with $16.27T in debt, giving a net cash position of -$16.18T billion.
Cash & Marketable Securities$88.86B
Total Debt$16.27T
Net Cash-$16.18T
Net Cash Per Share-$36.43K
Tangible Book Value Per Share$615.00K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oncotelic Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―